Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (NASDAQ: PSTX) is a clinical-stage biopharma leader developing non-viral allogeneic cell therapies and genetic medicines. This news hub provides investors and researchers with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access verified information about PSTX's CAR-T programs, gene editing innovations, and manufacturing advancements. Our curated collection includes press releases on clinical data readouts, FDA designations, collaboration expansions with partners like Roche, and financial performance updates.
Key content categories cover therapy development progress across oncology and rare diseases, technology platform enhancements, and business development activities. Bookmark this page for timely updates on Poseida's pioneering work in TSCM-rich cell therapies and its growing pipeline of precision genetic medicines.
Poseida Therapeutics (NASDAQ: PSTX) presented positive interim Phase 1 results for P-BCMA-ALLO1 in relapsed/refractory multiple myeloma patients, showing a 91% overall response rate in the optimized lymphodepletion arm (Arm C), including 100% response in BCMA-naïve patients. The therapy demonstrated favorable safety with no dose-limiting toxicities and low rates of side effects.
New data analysis revealed consistent P-BCMA-ALLO1 cellular expansion across patient subgroups, with an average manufacturing wait time of just 3.5 weeks. The company also presented promising preclinical data for P-CD19CD20-ALLO1, their dual CAR-T program, showing superior antitumor activity compared to single-targeting approaches.
Poseida Therapeutics (PSTX) has announced its acquisition by Roche Holdings in a deal valued at up to $1.5 billion. Shareholders will receive $9.00 per share in cash at closing, plus a non-tradeable contingent value right (CVR) worth up to $4.00 per share upon achieving specific milestones. The acquisition will establish Roche's core capability in allogeneic cell therapy, focusing on CAR-T programs. Poseida will join Roche's Pharmaceuticals Division, bringing its proprietary non-viral technology platform for developing TSCM-rich CAR-T therapies. The transaction is expected to close in Q1 2025, subject to customary conditions.
Poseida Therapeutics (PSTX) hosted a virtual R&D Day showcasing its allogeneic CAR-T therapy pipeline across hematologic malignancies, solid tumors, and autoimmune diseases. The company highlighted recent Phase 1 data for P-BCMA-ALLO1 and new preclinical findings for multiple programs. Key updates include P-CD19CD20-ALLO1's progress in B-cell malignancies, P-CD70-ALLO1's potential in AML, and P-BCMACD19-ALLO1's promising results in both autoimmune diseases and oncology. The company also presented innovative strategies for solid tumors through programs like P-MUC1C-ALLO1 and P-PSMA-ALLO1, leveraging their proprietary non-viral technology platform and TSCM-rich CAR-T approach.
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two major healthcare investor conferences. The company will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 10:20am ET, and the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 12:00pm ET.
Webcasts of both presentations will be accessible through Poseida's website and will remain available for approximately 90 days after the events.
Poseida Therapeutics (PSTX) reported strong Q3 2024 results, generating $71.7 million in revenue and achieving $20.2 million in net income. The company has been cash flow positive for the first nine months of 2024, securing $130 million in milestone and upfront payments. Their lead candidate P-BCMA-ALLO1 showed a 91% overall response rate in Phase 1 trials for multiple myeloma. The company expanded collaborations with Roche and Astellas, with cash runway extended into early 2026. Their cash position stands at $230.9 million as of September 30, 2024.
Poseida Therapeutics (PSTX) announced upcoming presentations of new data at two major conferences. At SITC 2024, the company will present preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) with enhanced potency for solid tumors. At ASH 2024, they will showcase additional patient response data from the P-BCMA-ALLO1 Phase 1 trial's Arm C and preclinical data from P-CD19CD20-ALLO1 for B-cell malignancies. Both therapies are being developed in collaboration with Roche. P-BCMA-ALLO1 has received RMAT designation for relapsed/refractory multiple myeloma patients.
Poseida Therapeutics (PSTX) announced new preclinical data for P-KLKB1-101, a liver-directed gene editing therapy for hereditary angioedema (HAE). The data demonstrated high-fidelity KLKB1 gene editing with off-target edits below 0.1%. In a humanized mouse model, a single dose achieved 58% reduction in kallikrein levels at 0.125 mg/kg, with effects lasting at least 180 days. Non-human primate studies showed favorable tolerability with liver editing approaching therapeutic range, and optimization yielded 29% increased potency. The company's proprietary lipid nanoparticle delivery system enabled controlled dose response.
Poseida Therapeutics (Nasdaq: PSTX) has announced the nomination of a new development candidate under its collaboration with Roche, triggering a $15 million milestone payment. The candidate is an allogeneic, dual CAR-T therapy targeting hematologic malignancies, including multiple myeloma. This nomination builds on their collaboration with Roche, showcasing Poseida's non-viral genetic engineering toolkit to create TSCM-rich allogeneic CAR-T therapies.
The company now has three programs under their collaboration with Roche, including P-BCMA-ALLO1 and P-CD19CD20-ALLO1. Poseida plans to host a Cell Therapy R&D Day on November 14th, 2024, to highlight progress across its pipeline. With this milestone payment, Poseida expects its cash position to be sufficient to fund operations into early 2026.
Poseida Therapeutics has been named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024, ranking #140. This recognition highlights the company's commitment to employee satisfaction and strong workplace culture. The list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI), surveyed over 2.6 million employees from various-sized businesses.
The evaluation focused on five critical areas: employees' positive feelings about their future at the company, career achievement, alignment of employer and employee values, respect at all levels, and collaboration. Additional factors like inclusion, diversity, equity, and career development were also considered.
Poseida's president and CEO, Kristin Yarema, Ph.D., emphasized the importance of employees in achieving the company's mission to develop new cell and gene therapies. The recognition reflects Poseida's strong culture, values, and commitment to both employees and patients.
Poseida Therapeutics reported positive interim Phase 1 results for its allogeneic CAR-T therapy P-BCMA-ALLO1 in relapsed/refractory multiple myeloma patients. The study showed a 91% overall response rate (ORR) in the optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients. Key findings include:
- High efficacy in heavily pretreated patients
- Differentiated safety profile with no dose-limiting toxicities
- Low rates of CRS and ICANS (all Grade 2 or less)
- No graft vs. host disease or Parkinsonism observed
P-BCMA-ALLO1 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The therapy is being developed in collaboration with Roche for blood cancers using Poseida's TSCM-rich CAR-T platform.
